Latest News

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China
2024-06-18

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China

Innovative drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets (Lumeblue®) is an oral diagnostic drug, approved by China’s NMPA for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The results of the Phase III clinical trial in China show that the Product can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint). The Product can be taken during the bowel preparation step, ensuring that colorectal staining is completed by the time colonoscopy is conducted. This not only enhances the detection rate of colorectal lesions but also potentially simplifies the colonoscopy procedure, making the examination more efficient and improving the screening benefits. As of now, CMS’s newly launched innovative portfolio has been expanded to 5 products, continuously generating driving force to the Group’s sustainable and healthy […]

Learn More
CMS Obtained Exclusive License of a Regenerative Collagen Light Medical Aesthetic Product Decellularized Extracellular Matrix Implant
2024-06-07

CMS Obtained Exclusive License of a Regenerative Collagen Light Medical Aesthetic Product Decellularized Extracellular Matrix Implant

• The Product, a collagen product with bioactive components, is under China’s registrational clinical trial stage. After validated by clinical trials and approved for marketing, it is expected to provide a medical aesthetic solution that could achieve instant physical filling of skin defects, endogenously induce collagen fiber regeneration, and promote tissue repair, achieving safe, natural, and refined rejuvenation effects. • The Product will synergize with CMS Skinhealth’s marketed Korean hyaluronic acid product and the regenerative pipeline products, including Poly-L-lactic Acid Microparticle Filler Injection, Polycaprolactone Microsphere Gel for Injection and Calcium Hydroxylapatite Microsphere Gel for Injection, providing consumers with comprehensive aesthetic solutions.   On June 7, 2024, the subsidiary of China Medical System Holdings Limited (“CMS”), a dermatology and medical aesthetic company “CMS Skinhealth” entered into an exclusive license agreement (“the license agreement”) with Shanghai Baiyiyuan Bioengineering Co., Ltd. (“Baiyiyuan Biotech”) for a light medical aesthetic injectable product, Decellularized Extracellular Matrix […]

Learn More
CMS Charity | Protecting Exceptional Children, Creating a Better Future
2024-06-04

CMS Charity | Protecting Exceptional Children, Creating a Better Future

China Medical System Holdings Limited (“CMS”) persists in showing deep concern for exceptional children and has supported the sustainable development of rehabilitation centers through donations during the past two years. Meanwhile, we have witnessed that many exceptional children successfully integrated into regular schools and received compulsory education with the help of rehabilitation training, laying a solid foundation for their future integration into society and healthy growth.   With Children’s Day approaching, CMS again made donations to Shenzhen Nanshan Star Exceptional Children Rehabilitation Center and Shenzhen Nanshan Exceptional Children Care Center through Charity Association of Shenzhen Nanshan. The donation will be directly used for the procurement and renewal of teaching tools and toys in both centers, enhancing the children’s sense of gain, happiness, and security, as well as providing supports for creating good education atmosphere, encouraging outstanding teachers, and improving teaching quality.     At yesterday’s event, representatives of CMS interacted […]

Learn More

The news on this page is intended to share cutting-edge medical information and is for academic reference only by medical and health professionals, not for advertising purposes. CMS does not recommend any drugs, medical devices and/or indications. The news information on this page is for reference only. Please follow the advice or guidance of your doctor or other healthcare professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. If you have understood and confirmed the above content, please click OK to enter.

All News